Frederick Askari, MD
Gastroenterology · Ann Arbor, MINPI 1689756108
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $370 of the $445 with a category attached, or 83.1%. AstraZeneca accounts for 83.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gastroenterology clinicians in MI, where the typical reported total is $1,620.
Across 2 payments — averaging $222.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$370
- Orphalan Inc$75
Across 125 payments — averaging $11,448 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1M
- Ultragenyx Pharmaceutical Inc.$387K
- Intercept Pharmaceuticals, Inc.$17K
What the payments were for
- Travel & lodging$37083%
- Food & beverage$7517%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $370 |
| Orphalan Inc | 1 | $75 |
How this compares
$445 in reported general payments places this provider in the 30th percentile of 497 gastroenterology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvriorTrientine Tetrahydrochloride | 22 | $348,781 |
| XifaxanRifaximin | 91 | $291,630 |
| Ursodiol | 180 | $40,288 |
| EliquisApixaban | 22 | $16,660 |
| Envarsus XrTacrolimus | 30 | $13,421 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $13,089 |
| Cyclosporine ModifiedCyclosporine, Modified | 69 | $12,113 |
| Tacrolimus | 127 | $11,603 |
| Trientine Hcl | 11 | $6,555 |
| VascepaIcosapent Ethyl | 12 | $4,051 |
| Azathioprine | 30 | $3,102 |
| Mycophenolate Mofetil | 25 | $3,006 |
| Lamivudine HbvLamivudine | 15 | $2,976 |
| Entecavir | 34 | $2,285 |
| Spironolactone | 68 | $1,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Orphalan IncCuvrior | $75 | $348,78122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 497 gastroenterology providers in Michigan.
Other gastroenterology in Ann Arbor
- Philip SchoenfeldAnn Arbor$539K
- Michelle Muza-MoonsAnn Arbor$481K
- Allison SchulmanAnn Arbor$124K
- Eric ShahAnn Arbor$120K
- Peter HigginsAnn Arbor$111K
- Neehar ParikhAnn Arbor$101K
- William CheyAnn Arbor$90K
- Ryan StidhamAnn Arbor$83K
- Elliot TapperAnn Arbor$69K
- Michael RiceAnn Arbor$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.